Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$114.22 - $140.1 $43,403 - $53,238
-380 Reduced 21.4%
1,396 $193,000
Q4 2023

Feb 13, 2024

BUY
$75.49 - $124.16 $9,511 - $15,644
126 Added 7.64%
1,776 $220,000
Q3 2023

Nov 14, 2023

BUY
$86.06 - $137.93 $258 - $413
3 Added 0.18%
1,650 $153,000
Q2 2023

Aug 14, 2023

BUY
$112.47 - $130.98 $12,034 - $14,014
107 Added 6.95%
1,647 $211,000
Q1 2023

May 15, 2023

BUY
$104.0 - $122.92 $39,520 - $46,709
380 Added 32.76%
1,540 $178,000
Q4 2022

Feb 14, 2023

BUY
$84.98 - $122.67 $64,584 - $93,229
760 Added 190.0%
1,160 $131,000
Q2 2022

Aug 15, 2022

BUY
$67.99 - $132.89 $20,397 - $39,866
300 Added 300.0%
400 $29,000
Q1 2021

May 14, 2021

BUY
$84.79 - $104.74 $4,239 - $5,237
50 Added 100.0%
100 $35,000
Q3 2020

Nov 12, 2020

SELL
$95.51 - $112.95 $4,106 - $4,856
-43 Reduced 46.24%
50 $20,000
Q2 2020

Aug 14, 2020

BUY
$62.68 - $105.34 $3,134 - $5,267
50 Added 116.28%
93 $37,000
Q1 2020

May 06, 2020

BUY
$47.79 - $75.63 $2,054 - $3,252
43 New
43 $11,000
Q1 2018

Apr 20, 2018

SELL
$13.06 - $18.54 $50,920 - $72,287
-3,899 Closed
0 $0
Q4 2017

Jan 22, 2018

BUY
$11.12 - $15.38 $43,356 - $59,966
3,899
3,899 $223,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $31B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.